Literature DB >> 23465426

Muscular dystrophies.

Eugenio Mercuri1, Francesco Muntoni.   

Abstract

Muscular dystrophies are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy. An improved understanding of their molecular bases has led to more accurate definitions of the clinical features associated with known subtypes. Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people. A better understanding of the mechanisms underlying the molecular pathogenesis of several disorders and the availability of preclinical models are leading to several new experimental approaches, some of which are already in clinical trials. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments.

Entities:  

Mesh:

Year:  2013        PMID: 23465426     DOI: 10.1016/S0140-6736(12)61897-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  162 in total

1.  Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy.

Authors:  Yasunari Matsuzaka; Soichiro Kishi; Yoshitsugu Aoki; Hirofumi Komaki; Yasushi Oya; Shin-Ichi Takeda; Kazuo Hashido
Journal:  Environ Health Prev Med       Date:  2014-08-24       Impact factor: 3.674

2.  Measuring quality of life in muscular dystrophy.

Authors:  Carla M Bann; Richard T Abresch; Barbara Biesecker; Kristin Caspers Conway; Chad Heatwole; Holly Peay; Peter Scal; Jonathan Strober; Karen Uzark; Jodi Wolff; Marjorie Margolis; Angela Blackwell; Natalie Street; Angela Montesanti; Julie Bolen
Journal:  Neurology       Date:  2015-02-06       Impact factor: 9.910

Review 3.  Laminin G-like domains: dystroglycan-specific lectins.

Authors:  Erhard Hohenester
Journal:  Curr Opin Struct Biol       Date:  2018-12-06       Impact factor: 6.809

4.  Use of state administrative data sources to study adolescents and young adults with rare conditions.

Authors:  J A Royer; J W Hardin; S McDermott; L Ouyang; J R Mann; O D Ozturk; J Bolen
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

5.  Premature termination codons in the DMD gene cause reduced local mRNA synthesis.

Authors:  Raquel García-Rodríguez; Monika Hiller; Laura Jiménez-Gracia; Zarah van der Pal; Judit Balog; Kevin Adamzek; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-02       Impact factor: 11.205

6.  Recent advances in muscle research.

Authors:  Jean M Sanger; Joseph W Sanger
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

7.  Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models.

Authors:  Roula Tsonaka; Mirko Signorelli; Ekrem Sabir; Alexandre Seyer; Kristina Hettne; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

8.  Lmo7 is dispensable for skeletal muscle and cardiac function.

Authors:  Dieu Hung Lao; Mary C Esparza; Shannon N Bremner; Indroneal Banerjee; Jianlin Zhang; Jennifer Veevers; William H Bradford; Yusu Gu; Nancy D Dalton; Kirk U Knowlton; Kirk L Peterson; Richard L Lieber; Ju Chen
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-08       Impact factor: 4.249

9.  DSS-induced damage to basement membranes is repaired by matrix replacement and crosslinking.

Authors:  Angela M Howard; Kimberly S LaFever; Aidan M Fenix; Cherie' R Scurrah; Ken S Lau; Dylan T Burnette; Gautam Bhave; Nicholas Ferrell; Andrea Page-McCaw
Journal:  J Cell Sci       Date:  2019-04-08       Impact factor: 5.285

10.  Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.

Authors:  Yongping Yue; Ibrahim M Binalsheikh; Stacey B Leach; Timothy L Domeier; Dongsheng Duan
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-17       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.